Mitoxana (Ifosfamide)

Ifosfamide is used in chemotherapy regimens targeting malignant cells in various solid tumours and lymphoid cancers.

• Testicular cancer: improves remission rates in advanced disease.
• Soft tissue sarcoma: reduces tumor size and prolongs progression‑free survival.
• Ovarian cancer: used in combination therapy for recurrent disease.
• Non‑small cell lung cancer: contributes to disease control in selected patients.
• Lymphoma: incorporated in protocols for refractory or high‑risk cases.

• Ifosfamide is a nitrogen‑mustard alkylating agent that forms covalent bonds with nucleophilic sites on DNA, primarily the N7 position of guanine. This alkylation creates intra‑ and interstrand cross‑links, obstructing DNA replication and transcription, ultimately triggering apoptosis in rapidly dividing tumor cells. The drug is a pro‑drug activated by hepatic microsomal enzymes to its active metabolite, which then exerts the DNA‑damaging effect.

Ifosfamide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea and vomiting: frequent gastrointestinal upset.
• Fatigue: generalized tiredness.
• Hemorrhagic cystitis: irritation of the bladder causing blood in urine.
• Myelosuppression: reduced white blood cells, red cells and platelets.
• Alopecia: temporary hair loss.

Serious or Rare Side Effects

• Nephrotoxicity: impaired kidney function.
• Neurotoxicity: confusion, seizures or encephalopathy.
• Severe infections: due to profound immunosuppression.
• Cardiotoxicity: rare heart muscle damage.
• Secondary malignancies: potential induction of new cancers.

When using Ifosfamide, clinicians should observe specific safety measures to minimize risks.

• Hydration: ensure adequate intravenous fluids before and after infusion to reduce bladder toxicity.
• Mesna co‑administration: give protective agent to prevent hemorrhagic cystitis.
• Renal function monitoring: assess serum creatinine and urine output regularly.
• Hematologic monitoring: perform complete blood counts to detect myelosuppression.
• Pregnancy and lactation: avoid use in pregnant or nursing women unless benefits outweigh risks.
• Store at ambient temperature: keep vials in original packaging, protect from light and moisture, and store below 25 °C.

Ifosfamide can interact with other medicines, altering its efficacy or toxicity profile.

Major Interactions (Avoid)

• Mesna dose mismatch: insufficient mesna increases risk of bladder toxicity.
• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma levels and toxicity.
• High‑dose radiation therapy: combined effect may exacerbate tissue damage.

Moderate Interactions (Monitor Closely)

• Anticoagulants (warfarin): enhanced bleeding risk due to platelet suppression.
• Other myelosuppressive agents (e.g., cyclophosphamide): additive bone‑marrow depression.
• Nephrotoxic drugs (e.g., aminoglycosides): increased risk of kidney injury.